Who founded Freenome?

Freenome was founded by Riley Ennis, Charles Roberts, Gabriel Otte in 2015.

Who are Freenome's investors?

Freenome's investors include RA Capital, AME Cloud Ventures, Andreessen Horowitz, Artis Ventures, Asset Management Company, Averin Capital, Bain Capital Life Sciences, Catalio Capital Management, LP and 7 more.

How much funding has Freenome raised?

Freenome has disclosed $800K raised across 1 round.

Where is Freenome headquartered?

Freenome is headquartered in London.

Freenome

NASDAQ: FRNM

London · Founded 2015 · United Kingdom corporation · 15 known investors

freenome.com ↗

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.

AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Freenome was founded in 2015 by Riley Ennis, Charles Roberts, and Gabriel Otte.

Riley EnnisCo-Founder and Chief Product Officer

Charles RobertsinCo-founder

Gabriel OtteinCEO, Co-founder2016–2021

Board

Stuart LawsonBoard director

Investors · 15

RA Capital✓ verifiedBoston

AME Cloud VenturesPalo Alto · $1M – $10M

Andreessen HorowitzMenlo Park · $500K – $50M

Artis VenturesSan Francisco · $50K – $25M

Asset Management CompanyMenlo Park · $500K – $2M

Averin CapitalNew York

Bain Capital Life SciencesBoston

Catalio Capital Management, LPNew York

CRV (Charles River Ventures)San Francisco · $250K – $5M

DCVC (Data Collective)Palo Alto · $5M – $25M

EcoR1 CapitalSan Francisco

GV (Google Ventures)Mountain View · $250K – $50M

Kaiser Permanente VenturesSan Francisco · $2M – $5M

Roche Venture FundBasel · $648K – $3.2M

Agent CapitalreportedWaltham

Reported raises · per SEC filings

Form D private placements

$800K disclosed across 1 round · 2015

▶$800KraisedOct 2015 · 4 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Stuart LawsonDirector
Charles RobertsDirector
Gabriel OtteDirector

Offering amount: $800K
Amount sold: $800K
First sale: Oct 2015
Incorporated: Corporation, United Kingdom, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

The Freenome mafia →

6 people who came through Freenome went on to found or lead other companies.

Amir NashatBoard MemberFounded Paratus Sciences +1 Jonathan HirschAdvisor, Real World Evidence & Data PlatformFounded Synapticure Jay ChiaML Infrastructure EngineerFounded Eventual Abhinav GopalSoftware EngineerFounded Rubbrband David WeinbergPrincipal ScientistFounded ParcelBio Dima VremenkoSoftware Engineer InternFounded Inkbox

Competitors · 10

by search overlap

Immunome29 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

Myome21 shared keywordsMyOme uses whole genome sequencing and bioinformatics to analyze a single patient sample and produce clinically actionable reports, offering both proactive health tests (such as polygenic risk scores and medication response) and diagnostic tests for rare disease. Its genomic testing serves healthcare providers, patients, employers, and health systems to guide prevention, treatment, and lifestyle decisions.

Alterome Therapeutics, Inc.21 shared keywordsAlterome develops targeted, genomically-defined cancer therapies aimed at aggressive cancers that lack effective treatment options, focusing on more precise drugs with fewer off-target effects. It serves cancer patients by targeting disease-driving genetic alterations.

Cellanome20 shared keywordsCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.

Noveome Biotherapeutics20 shared keywordsNoveome is a biopharmaceutical company developing ST266, a multi-targeted secretome biologic containing biologically active proteins and factors aimed at neuroprotection, inflammation modulation, and cell recovery. The company is targeting underserved conditions in ophthalmology, neurology, and dermatology.

Genomeweb18 shared keywordsGenomeWeb's Research Funding section publishes news coverage of research grants and government funding trends in genetics, genomics, and molecular diagnostics. It is an industry news publication serving researchers and organizations in the life sciences.

Bioworld17 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Metronome17 shared keywordsMetronome provides a usage-based billing platform for SaaS companies, enabling them to launch products faster and make data-driven revenue decisions. The platform handles billing operations at scale, allowing companies to iterate pricing strategies and connect billing to product experiences.

healthOme16 shared keywordsHealthHome offers Kadance, a precision cancer management service that combines genomic science with expert health navigation to help individuals with cancer risk assessment, treatment planning, and recovery. It is sold to individuals as well as insurance carriers and agents as an add-on to critical illness or life insurance policies.

Nucleome15 shared keywordsNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.

Companies competing with Freenome for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Freenome Raises $65M in Series A from Andreessen Horowitz, GV and Othersmedium.com · Mar 2017

Frequently asked questions

What does Freenome do?: Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.
Who founded Freenome?: Freenome was founded by Riley Ennis, Charles Roberts, Gabriel Otte in 2015.
Who are Freenome's investors?: Freenome's investors include RA Capital, AME Cloud Ventures, Andreessen Horowitz, Artis Ventures, Asset Management Company, Averin Capital, Bain Capital Life Sciences, Catalio Capital Management, LP and 7 more.
How much funding has Freenome raised?: Freenome has disclosed $800K raised across 1 round.
Where is Freenome headquartered?: Freenome is headquartered in London.